Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

478 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.
La Rosa AM, Harrison LJ, Taiwo B, Wallis CL, Zheng L, Kim P, Kumarasamy N, Hosseinipour MC, Jarocki B, Mellors JW, Collier AC; ACTG A5273 Study Group. La Rosa AM, et al. Among authors: mellors jw. Lancet HIV. 2016 Jun;3(6):e247-58. doi: 10.1016/S2352-3018(16)30011-X. Epub 2016 Apr 18. Lancet HIV. 2016. PMID: 27240787 Free PMC article. Clinical Trial.
The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan.
DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L, Mellors J. DeGruttola V, et al. Antivir Ther. 2000 Mar;5(1):41-8. doi: 10.1177/135965350000500112. Antivir Ther. 2000. PMID: 10846592
Antiretroviral-drug resistance among patients recently infected with HIV.
Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD. Little SJ, et al. Among authors: mellors jw. N Engl J Med. 2002 Aug 8;347(6):385-94. doi: 10.1056/NEJMoa013552. N Engl J Med. 2002. PMID: 12167680 Free article.
Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.
Collier AC, Tierney C, Downey GF, Eshleman SH, Kashuba A, Klingman K, Vergis EN, Pakes GE, Rooney JF, Rinehart A, Mellors JW; AIDS Clinical Trials Group Protocol A5143 Team. Collier AC, et al. Among authors: mellors jw. HIV Clin Trials. 2008 Mar-Apr;9(2):91-102. doi: 10.1310/hct0902-91. HIV Clin Trials. 2008. PMID: 18474494 Clinical Trial.
Class-sparing regimens for initial treatment of HIV-1 infection.
Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW; AIDS Clinical Trials Group Study A5142 Team. Riddler SA, et al. Among authors: mellors jw. N Engl J Med. 2008 May 15;358(20):2095-106. doi: 10.1056/NEJMoa074609. N Engl J Med. 2008. PMID: 18480202 Free PMC article. Clinical Trial.
Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.
McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S, McNulty S, Metcalf JA, Acosta E, Rehm C, Coffin JM, Mellors JW, Maldarelli F. McMahon D, et al. Among authors: mellors jw. Clin Infect Dis. 2010 Mar 15;50(6):912-9. doi: 10.1086/650749. Clin Infect Dis. 2010. PMID: 20156060 Free PMC article.
478 results